A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Lenvatinib (Primary)
- Indications Leiomyosarcoma; Liposarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms LEADER
- 04 Jun 2019 Results from Phase Ib portion published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 23 Jul 2018 Status changed from not yet recruiting to recruiting.
- 18 May 2018 New trial record